Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:27:48.567Z.
Consensus retrieved: 2026-10-06T14:44:08.783Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:27:48.567Z.
Quote observation: 2026-10-06T18:25:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3fedda3e1734a3f2f81fff07af8d697ed427ce7ca7e5fb1d4bfa48f68cdcbd57
FORWARD PE RATIO
N/A
Organigram Global Inc.
Market Cap
$136.54M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Organigram Global Inc. (OGI) | $136.54M | N/A |
| Freenome, Inc. (FRNM)vs › | $135.86M | N/A |
| LifeMD, Inc. (LFMD)vs › | $134.21M | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.61M | N/A |
| Atrium Therapeutics, Inc. (RNA)vs › | $138.04M | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $133.33M | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $132.84M | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | N/A |
| Immuneering Corporation (IMRX)vs › | $140.67M | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $141.49M | N/A |
Trailing P/E
2.2
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
Consensus estimates for this stock are reported in CAD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
